Related Experiment Videos
[Issues in cancer treatments--EBM, individuation, and standardization]
1Division of Internal Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuou-ku, Tokyo 104-0045, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 30, 2001
Summary
Japanese doctors must integrate evidence-based medicine (EBM) with personalized cancer treatments. Conducting more clinical trials in Japan is crucial for generating relevant evidence and advancing individualized cancer care.
Area of Science:
- Oncology
- Medical Research Methodology
- Evidence-Based Medicine
Context:
- The integration of evidence-based medicine (EBM) into Japanese medical practice began in the 1990s.
- Recent molecular biology advances enable customized cancer treatments, with some personalized therapies now approved drugs.
- A gap persists in understanding EBM, potentially leading to the justification of experimental treatments lacking sufficient evidence.
Purpose:
- To review the origins and methodology of EBM.
- To discuss the concept of individualized cancer treatment.
- To argue for the necessity of standardized-individuated-treatments.
Summary:
- This review highlights the critical need for Japanese physicians to base individualized cancer patient treatments on evidence-based medicine (EBM).
- Increased participation in clinical trials within Japan is essential for generating applicable evidence and refining the analysis of international trials.
- The article addresses the evolution of EBM, the nuances of treatment individualization, and advocates for a framework of standardized-individuated-treatments.
Impact:
- Enhances understanding of EBM principles in oncology.
- Promotes the development and application of personalized cancer therapies.
- Provides a framework for evidence-based, individualized treatment strategies in Japan.